Opinion|Videos|February 26, 2025

KRAS Inhibitors for NSCLC: Efficacy and Safety

Author(s)Joshua K. Sabari, MD, Christine Bestvina, MD , Mark Kris, MD

Panelists discuss the efficacy and safety of KRAS inhibitors for non–-small cell lung cancer (NSCLC), evaluating clinical trial results and their potential impact on treatment strategies.

Episodes in this series

EP. 1 Overview: Actionable Alterations in NSCLC

EP. 1 Overview: Actionable Alterations in NSCLC

EP. 2 Molecular Testing for Metastatic NSCLC

EP. 2 Molecular Testing for Metastatic NSCLC

EP. 3 Metastatic NSCLC: Decision-Making When Molecular Testing Results Are Delayed

EP. 3 Metastatic NSCLC: Decision-Making When Molecular Testing Results Are Delayed

EP. 4 Use of RNA-Based Molecular Panels in Metastatic NSCLC

EP. 4 Use of RNA-Based Molecular Panels in Metastatic NSCLC

EP. 5 Case 1 Presentation—KRAS-Mutated Metastatic NSCLC: First-Line Decision- Making

EP. 5 Case 1 Presentation—KRAS-Mutated Metastatic NSCLC: First-Line Decision- Making

EP. 6 Case Presentation: Second-Line Decision- Making for KRAS-Mutated Metastatic NSCLC

EP. 6 Case Presentation: Second-Line Decision- Making for KRAS-Mutated Metastatic NSCLC

EP. 7 KRAS Inhibitors for NSCLC: Efficacy and Safety

EP. 7 KRAS Inhibitors for NSCLC: Efficacy and Safety

EP. 8 KRAS-Mutated Metastatic NSCLC: Individualized Treatment Selection

EP. 8 KRAS-Mutated Metastatic NSCLC: Individualized Treatment Selection

EP. 9 KRAS Inhibition: On the Horizon

EP. 9 KRAS Inhibition: On the Horizon

EP. 10 Case 2—Metastatic NSCLC With a ROS1 Alteration: Presentation and Discussion

EP. 10 Case 2—Metastatic NSCLC With a ROS1 Alteration: Presentation and Discussion

EP. 11 Next-Generation ROS1 Inhibition

EP. 11 Next-Generation ROS1 Inhibition

EP. 12 Treatment Decision-Making for Metastatic NSCLC With a ROS1 Alteration

EP. 12 Treatment Decision-Making for Metastatic NSCLC With a ROS1 Alteration

EP. 13 ROS1 Inhibition: AE Management

EP. 13 ROS1 Inhibition: AE Management

EP. 14 Case 2 (cont.)—Metastatic NSCLC With a ROS1 Alteration: Patients With CNS Disease

EP. 14 Case 2 (cont.)—Metastatic NSCLC With a ROS1 Alteration: Patients With CNS Disease

EP. 15 Case 3—HER2-Mutated Metastatic NSCLC: Presentation and Discussion

EP. 15 Case 3—HER2-Mutated Metastatic NSCLC: Presentation and Discussion

EP. 16 HER2 Mutations in NSCLC

EP. 16 HER2 Mutations in NSCLC

EP. 17 HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging Approaches

EP. 17 HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging Approaches

EP. 18 Management of ADC-Related AEs

EP. 18 Management of ADC-Related AEs

EP. 19 Case 3 (cont.): Management of Treatment-Associated ILD/Pneumonitis

EP. 19 Case 3 (cont.): Management of Treatment-Associated ILD/Pneumonitis

Newsletter

Stay up to date on practice-changing data in community practice.

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Kamel Abou Hussein, MD; Yan Ji, MD, PhD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Virginia Kaklamani, MD, DSc; Denise Yardley, MD, GCRA

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Kamel Abou Hussein, MD; Kit Y Lu, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP

Washington State Medical Oncology Society

Washington State Medical Oncology Society

2 Sessions are Available!

Nevada Oncology Society

Nevada Oncology Society

2 Sessions are Available!

Wyoming State Oncology Society

Wyoming State Oncology Society

2 Sessions are Available!

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Module 4: Breast Surgery (2025)

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Module 5: Breast Radiation Therapy (2025)

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Module 3: Pathology And Biomarkers (2025)

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Module 2: Breast Imaging (2025)

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Module 9: Toxicity Management And Survivorship Considerations (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Dr Pant Discusses Next Steps in Daraxonrasib Development for Pancreatic Cancer

FDA Expands Sevabertinib Approval to Treatment-Naive HER2-Mutant NSCLC

Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC

High Rate of Papillary Thyroid Cancer Overdiagnosis Shown in Simulation Study

Arlo-Cel Meets Efficacy End Point in Quadruple-Class Exposed Myeloma